ESCaPE-CMD (CLBS16)

Study Information

ESCaPE-CMD is a Phase 2 study evaluating an autologous CD34+ cell therapy (CLBS16) for the treatment of coronary microvascular dysfunction (CMD) at two centers in the United States. For more information on this study, please visit www.escapecmd.com.

Status: Study Complete